ABSTRACT
The prevention or treatment of rhinovirus infections has been attempted in many clinical trials since the discovery of the virus in 1956. In spite of the effort and resources that have been expended in this endeavor, no antiviral drugs are currently marketed for the prevention or treatment of rhinovirus infection. Recent studies of the pathogenesis of rhinovirus infections suggest that the host response contributes to the symptom complex associated with these infections (2-5). Inhibition of both the inflammatory response and viral replication may be required for a clinically significant effect on the rhinovirus colds.
